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Low- and middle-income countriesPneumococcal disease is a leading cause of childhood mortality, globally. The pneumococcal conjugate
vaccine (PCV) has been introduced to many countries worldwide. However there are few studies evalu-
ating PCV impacts in low- and middle-income countries (LMIC) because measuring the impact of PCV on
pneumococcal disease in LMICs is challenging. We review the role of pneumococcal carriage studies for
the evaluation of PCVs in LMICs and discuss optimal methods for conducting these studies. Fifteen car-
riage studies from 13 LMICs quantified the effects of PCV on carriage, and identified replacement carriage
serotypes in the post-PCV era. Ten studies reported on the indirect effects of PCV on carriage. Results can
be used to inform cost-effectiveness evaluations, guide policy decisions on dosing and product, and mon-
itor equity in program implementation. Critically, we highlight gaps in our understanding of serotype
replacement disease in LMICs and identify priorities for research to address this gap.
 2019 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
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Infections due to Streptococcus pneumoniae, including pneumo-
nia and meningitis, are a leading cause of morbidity and mortality,
especially in low- and lower middle-income countries (LMICs)
worldwide [1]. Two pneumococcal conjugate vaccines (PCVs) are
currently licensed for use in children: the 10-valent PCV (Synflorix,
GlaxoSmithKline) and the 13-valent PCV (Prevenar 13, Pfizer). They
protect against the most common invasive paediatric serotypes of
>90 pneumococcal serotypes.
Post-licensure evaluations of PCVs, predominantly in high-
income countries (HIC), demonstrated dramatic reductions in
pneumococcal disease following vaccine introduction [2]. These
reductions include direct effects on vaccinated children, as well
as indirect effects across the whole population. Indirect effects
are mediated through reductions in carriage and transmission of
vaccine-type (VT) pneumococci [2–4] and comprise a substantial
proportion of overall effects, driving the cost-effectiveness of the
vaccine [5]. However, reductions in VT carriage have led to a corre-
sponding increase in carriage of non-vaccine serotypes (NVT) (i.e.
serotype replacement) [6]. Serotype replacement threatens to
undermine the public health gains of PCV introduction, especially
among older populations who initially benefited from strong indi-
rect effects. While serotype replacement in carriage occurs in all
settings, the amount of replacement disease caused is highly vari-
able and the reasons for this are not known [7].
While PCV has been introduced in 144 countries worldwide,
there are relatively few studies on the impact of PCV in LMICs
[8]. Evaluations of vaccine impact in LMICs are critical because
there are key differences in pneumococcal epidemiology, including
higher pneumococcal transmission rates [9], which means that
studies conducted in HIC are not directly applicable. A recent
review highlighted the striking geographical differences in sero-
type replacement disease in predominantly high-income countries,
but in many LMICs the degree of replacement disease and respon-
sible serotypes is not known [7].
Monitoring pneumococcal serotypes and determining PCV
impact in LMIC is difficult because the recommended method for
assessing vaccine impact, invasive pneumococcal disease (IPD)
surveillance, is often not feasible [10]. In 2017, the World Health
Organization’s Invasive Bacterial Vaccine Preventable Diseases
(IB-VPD) global surveillance network, which monitors invasive
bacterial diseases, identified just 116 and 55 confirmed IPD cases
from the two regions with the highest burden of IPD (Africa and
South-East Asia), respectively [11]. These data are insufficient to
make policy decisions regarding PCV introduction in LMIC, includ-
ing choice of the valency of vaccine, vaccine schedule and whether
or not to introduce the vaccine [12].
Carriage studies have been used as an adjunct to IPD surveil-
lance and pneumonia studies for assessing PCV impact and mon-
itoring pneumococcal serotypes in LMIC. Reductions in VT
carriage following PCV introduction likely correspond to reduc-Downloaded for Anonymous User (n/a) at Royal Children's Hospital - J W
For personal use only. No other uses without permissiotions in VT disease, since carriage is a precursor for disease
[13]. Carriage studies are easier to conduct, since sample collec-
tion is less invasive; and require smaller sample sizes, as inci-
dence and prevalence of pneumococcal carriage are higher than
that of IPD. It is challenging to identify the aetiological agent
of pneumonia, whereas pneumococcal carriage can be more
easily be identified and used to demonstrate the biological
effects of PCV on specific serotypes.
There are multiple potential uses of carriage studies for the
evaluation of PCVs. Carriage studies can demonstrate the effec-
tiveness of the vaccine against VTs in vaccinated individuals
(direct and indirect [i.e. total effects]) and quantify reductions
in transmission of VTs to unvaccinated individuals (indirect
effects). They can also be used to monitor which serotypes
increase in prevalence as VT carriage decreases, which provides
an indication of the common circulating serotypes post-PCV
introduction which may cause disease. Data from carriage stud-
ies can be incorporated into analytical models, alongside infor-
mation about the serotype-specific invasiveness, to predict
impacts on disease [14,15]. These results have important policy
implications and can be used to inform cost-effectiveness evalu-
ations, guide policy decisions on dosing and product, and moni-
tor equity in program implementation.
Despite the potential importance of carriage studies for evaluat-
ing PCV, and a growing body of literature, there is limited discus-
sion or consensus on the methods for conducting these studies or
their interpretation. Current guidelines provided by the World
Health Organization focus on carriage methodologies [16], and
on measuring the impact of PCV using IPD or pneumonia surveil-
lance [10]. Therefore, we aim to review the utility of carriage stud-
ies for evaluating PCV and discuss optimal methods for conducting
these studies.
2. Scope of the review
This review has three sections. First, we review the current lit-
erature on pneumococcal carriage studies for evaluating PCV in
LMIC. Second, we discuss the value of carriage studies for inform-
ing PCV policy, and highlight remaining gaps in using carriage
studies for PCV program evaluation in LMIC. Lastly, we discuss
the implications of different study designs for the interpretation
of results and identify optimal designs for future carriage studies.
We adhere to previously defined terminology regarding vaccine
evaluations [17,18]. In brief, vaccine effectiveness is a measure of
direct effects, under field conditions, while vaccine impact encom-
passes both direct and indirect effects.
We have restricted our discussion to study types suitable for the
routine evaluation of PCV programs at a population level (e.g.
cross-sectional studies). We exclude data from longitudinal studies
and cluster-randomised controlled trials since these study designs
are more resource-intensive and better suited to answer specific
research questions. Grieve Lib from ClinicalKey.com.au by Elsevier on March 24, 2021.
n. Copyright ©2021. Elsevier Inc. All rights reserved.
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Our search identified 26 LMICs with ongoing or completed PCV
impact studies using nasopharyngeal carriage as an outcome (Sup-
plementary Table 1 [90–95]). There were 15 published or pre-print
studies from 13 countries available for this review. All except one
were serial or single cross-sectional studies, with one study in Tur-
key conducting prospective carriage surveillance. All 15 studies
were conducted in healthy participants, recruited either from the
community or from health facilities. The majority (n = 7) were con-
ducted in the African region. The earliest study was published in
2013 and the greatest number of studies were published in 2018
(n = 5), indicating this is a relatively new and growing area of
study. All included studies were found to be at either a moderate
or serious risk of bias. The main issue was the degree to which con-
founding factors were either measured or adjusted for.
3.1. Total effects
Carriage studies in LMIC have consistently reported substantial
declines in VT carriage among children within targeted age groups,
who benefit from both direct and indirect effects, following PCV
introduction (Table 1). For example, in Kenya the prevalence of
VT carriage two years following PCV10 introduction among chil-
dren under five years of age decreased by 64% (PR 036, 95%CI
026-051) [19].
Four studies of the included studies examined trends in VT car-
riage density (Table 1), which is of interest due the potential role of
carriage density in disease (pneumonia) and transmission [20–22].
Only one study, in Fiji, showed a decline in VT carriage density,
three years post-PCV introduction, however there were declines
in overall pneumococcal carriage density over the same period,
indicating the results may not be attributable to vaccine effects
[23]. More research is needed to understand the inconsistent
results from field-based studies.
3.2. Direct effects
A single study from Brazil reported vaccine effectiveness of
three doses of PCV13 of 44.0% (14.2–63.5) against VT carriage
among children 7–11 months of age. The study was conducted
one year after vaccine introduction, and while the PCV coverage
at the time was not reported, 83% of the study population had
received at least one dose of PCV [24]. We note that a second study
from Brazil also reported vaccine effectiveness, however the
unvaccinated group included both children before and after vac-
cine introduction and therefore reported vaccine effectiveness is
in fact a composite measure of both direct and total effects.
Accordingly, their estimates of vaccine effectiveness were much
higher (927% [796, 974] for three doses of PCV10) [25].
3.3. Indirect effects
Of the 10 studies reporting on indirect effects in older children
and adults, all but two studies, both in The Gambia, report some
evidence of indirect effects (Table 1). In The Gambia, the VT car-
riage prevalence in mothers of vaccinated children remained at
similar levels following PCV introduction (6.6% pre-PCV, 8.4% one
year post-PCV [first study], and 5.6% five years post-PCV [second
study] [26]. Among the five studies that report on infants too
young to be vaccinated, four studies reported a decline in VT car-
riage (with only two studies from Fiji and Mongolia achieving sta-
tistical significance) [23,27–29]. In Malawi, indirect effects were
observed in mothers and older children but not among infants,
indicating indirect effects on the infant age group may be harderDownloaded for Anonymous User (n/a) at Royal Children's Hospital - J W G
For personal use only. No other uses without permission. Cto achieve than for older age groups [27]. The differences in indi-
rect effects are likely a result of different contact patterns between
age groups, alongside differences in naturally acquired immunity
[27].
Despite the majority of studies reporting declines in VT carriage
among unvaccinated age groups, indicating evidence of indirect
effects, many sites, especially in the African region, have reported
persistence of VT carriage at high levels in unvaccinated age groups
suggesting that full indirect effects are yet to be seen [26–28,30].
This contrasts with studies from HIC such as the US, where carriage
of VT serotypes across all age groups were less than 5% four years
after vaccine introduction [31]. Ongoing VT transmission despite
high levels of coverage is likely due to the higher baseline rates
of pneumococcal carriage and transmission [9].
3.4. Serotype replacement in carriage
While VT carriage prevalence declines, overall pneumococcal
carriage prevalence remained constant, with replacement by NVTs.
All studies demonstrated an increase in NVT carriage rates among
vaccinated children. And all studies demonstrated either an
increase or non-significant decrease in NVT carriage among unvac-
cinated children and adults post-PCV introduction, except a study
from the early post-PCV period in South Africa, which found a sig-
nificant decrease in NVTs among individuals >12 years of age.
(Supplementary Table 5) We are undertaking a global meta-
analysis to compare regional and temporal variations in
serotype-specific carriage post-PCV introduction. This will provide
critical information to better understand whether differences in
replacement carriage serotypes can account for differences in ser-
otype replacement disease observed across different settings.
3.5. Implications for vaccine policy
3.5.1. Informing policy decisions on dosing and product
While carriage studies provide useful information on the impact
of PCV on circulating serotypes of pneumococcus, ultimately what
is of relevance to policy makers is the impact on disease outcomes.
There is substantial heterogeneity in the relative impact of PCV on
pneumococcal disease across settings. Understanding the factors
that explain this heterogeneity can inform policy recommenda-
tions to maximise impacts [2,4].
Carriage studies may help determine the optimal schedule for
PCV programs in LMIC. The relative effectiveness of differing vac-
cine schedules remains contentious. A systematic review compiled
for the WHO Strategic Advisory Group of Experts (SAGE) on Immu-
nization in 2017, suggested that there is no evidence of difference
between the two most common schedules (three infant doses [3
+ 0] or two infant doses plus booster [2 + 1]) in either direct or indi-
rect effects against carriage or IPD [38]. At the time, Australia was
the only HIC using a 3 + 0, however, in 2018, policy makers chan-
ged to a 2 + 1 schedule based on data on vaccine failures in older
children and indirect effects. [39,40] This is supported by results
from a meta-regression of carriage studies, showing waning of
PCV7 effectiveness with a 3 + 0 schedule compared to a 2 + 1
schedule [41]. An updated of this analysis is warranted, given the
availability of more carriage studies from LMIC.
One the key challenges in using carriage studies to compare
schedules is the expected heterogeneity in vaccine impact across
different settings, as a function of variability in effectiveness of
the vaccine, PCV coverage and timeliness of administration, as well
as baseline pneumococcal epidemiology. Meta-regression tech-
niques may be helpful to better understand how such explanatory
variables might influence the intervention effect size. Standardis-
ing study designs and analysis methods, including period of obser-
vation post-PCV introduction, may also help researchers torieve Lib from ClinicalKey.com.au by Elsevier on March 24, 2021.
opyright ©2021. Elsevier Inc. All rights reserved.
Table 1
Summary of published studies evaluating pneumococcal conjugate vaccine impact using carriage in low- and middle-income countries.
WHO
Region




No. years post-PCV PCV
Coverage§









Healthy children up to












87% Infants (18 weeks): VT carriage decreased from
451% to 91%; aPR 024 (008–075)
Children (1–4 years), vaccinated: VT carriage
decreased from 282 to 165%, aPR 054 (033–088)
Infants (6 weeks): VT carriage




decreased from 282 to 229%
aPR 084 (053–133)
Children 5–15 years: VT
carriage decreased from 212 to
79%; aPR 037 (017–078)
HIV-negative mothers: VT
carriage decreased from 66 to







Healthy children (6 weeks
 59 months); recruited











80% 6 weeks–11 months, vaccinated*: VT carriage
decreased from 366 to 206%; PR 056 (032–099)
p = 004
12–23 months, vaccinated*: VT carriage decreased
from 351 to 209%; PR 059 (037–097) 003
24–59 months, vaccinated*: VT carriage decreased
from 360 to 167%; PR 046 (008–280) 040
< 5 years, all:
No changes in density for serotypes 19A and 19F
6 weeks–11 months,
unvaccinated**: VT carriage
decreased from 366 to 250%; PR
068 (019–236)
24–59 months, unvaccinated**:
VT carriage decreased from 360







Healthy population of all











75% <5 years: VT carriage decreased from 34 to 13%; aPR
036 (026–051)
5 years: VT carriage decreased















2 years post PCV
introduction, compared
to survey conducted
same year as PCV
introduction
72% < 2 years old: VT carriage decreased from 451 to
235%, p < 00001; aRR 050 (042–059)
6–12 years old: VT carriage
decreased from 19 to 126%; aRR
066 (048–092)
13–18 years old: VT carriage
decreased from 57 to 21%; aRR
049 (017–139)
19–45 year old: VT carriage
decreased from 3% to 11%; aRR
036 (018, 074)
 45 years old: VT carriage


















2 years post PCV13
introduction compared
to PCV7 (and pre-
PCV13) era
62% < 9 months old: VT carriage decreased from 252 to
136%; aOR 052(034, 079)
9–24 months old: VT carriage decreased from 422 to
148%; aOR 026 (016, 041)
24–48 months old: VT carriage decreased from
421 to 155%; aOR 025 (017, 036)
4–12 years old: VT carriage
decreased from 343 to 224%;
aOR 052 (037, 075);
Mothers: VT carriage decreased









11 months) and mothers;









90% 6–11 months old: VT carriage decreased from 333 to
114%; aRR 060 (050,071), p < 0001
Mothers: VT carriage similar in
all three surveys (6.6%, 8.4%,
5.6%); aRR 092 (067,127),
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11 months) and mothers;








98% 6–11 months old: VT carriage decreased from 33.3 to
183%; aRR 055 (042,072), p < 0001
Mothers:
VT carriage increased from 66 to









Healthy children  5 years









N/A VT carriage decreased from 419 to 19%; relative






































same year as PCV
introduction
94% VT carriage decreased from 198 to 18%; VE against
VT carriage: 2 doses  878% (49, 984); 3 doses 






























up to 2 years post;
vaccinated compared to
unvaccinated
97% OR 061 (041–091), p = 001, no association in
adjusted analysis (not reported)
S




8 week, 12–23 month, 2–
6-years), and caregivers;







3 years post PCV
introduction, compared
to pre-PCV introduction
99% 12–23 months old: VT carriage decreased from 223
to 73%; aPR 034 (023–049); median VT density
reduced from 498 to 429 log10 GE/mL, p = 0024;
density lower in vaccinated compared to vaccinated
(adjusted coefficient 056, 95%CI 098 to 015,
p = 0008)
2–6 years old: VT carriage decreased from 217 to
91%; aPR 047 (034–066)
5–8 weeks old: VT carriage
decreased from 96 to 58%; aPR
056 (95% CI 034–093);
Caregivers: VT carriage









8 weeks, 12–23 months);
recruited from maternal






2 years post PCV
introduction compared
to pre-PCV introduction
83% 12–23 months old: VT carriage decreased from 329
to 198%; aPR 077 (061  096); median VT density
increased from 550 to 599 log10 GE/mL, p = 0006;
density higher in vaccinated compared to
unvaccinated (adjusted coefficient 040, 95% CI 007-
073, p = 0017)
5–8 weeks old: VT carriage
decreased from 65 to 52% aPR
074 (043  127);
median VT density increased









8 week and 12–
23 months); recruited






1 year post PCV
introduction compared
to pre-PCV introduction
97%y 12–23 months old: VT carriage decreased from 422
to 197%; aPR 047 (038  058); median VT density
increased, p < 0.001; vaccinated compared to
unvaccinated (coefficient 0.58, 95% CI 0.19–0.97,
p = 0.004)
5–8 weeks old: VT carriage
decreased from 12.9 to 6.3%; aPR
049 (033  074); median VT
density increased, p < 0.001
M
Abbreviations: aOR = adjusted odds ratio, OR = odds ratio, aPR = adjusted prevalence ratio, VE = vaccine effectiveness, GE = genome equivalents, M = moderate, S = serious, N/A = not available; P-values included where provided.
* Vaccinated defined as having received three doses.
** Unvaccinated defined as having received no doses.
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in the biological effect of different schedules. This is particularly
important when making comparisons between vaccine schedules,
since differences in effect sizes are likely to be smaller.
Another key question in the field is the potential use of reduced
dose schedules. Following the control of VT disease, transitioning
to a schedule comprising of a single priming followed by a booster
dose (1 + 1) may be sufficient to sustain VT disease control at
reduced costs [42]. The success of this approach will largely be
determined by the schedule’s ability to maintain indirect protec-
tion for infants receiving insufficient doses for direct protection.
In LMICs, different strategies may be required to achieve and main-
tain control of VTs [9,43,44]. Modelling from Malawi and Kenya
indicate that VT elimination is unlikely, despite high vaccine cover-
age using a 3 + 0 schedule for period of six to ten years [45,46].
Vaccine programs may need to cover broader age ranges and use
different schedules to control VT transmission [9,43,44]. Carriage
studies can also highlight target age groups for control of VT strains
and identify settings which have successfully eliminated VT trans-
mission and are suitable reduced dose schedules.
Monitoring of serotype replacement disease, in particular,
remains a critical gap within LMICs. In the absence of IPD data in
many LMIC, it is not known the degree to which reductions in VT
disease have been supplanted by increases in NVT disease. Data
on replacement serotypes is also important to inform the develop-
ment of higher-valency vaccine formulations. Discussion of
whether carriage studies can be used to model replacement dis-
ease are discussed further below.
3.5.2. Modelling vaccine impact on disease
There are a number of studies that have modelled the impact of
PCV on both VT and NVT IPD using carriage data. A method pro-
posed by Weinberger et al. employs static regression models pop-
ulated by a combination of pre-PCV IPD data and change in VT
carriage before and after PCV introduction to estimate impact of
PCV on overall IPD [14]. This method has been validated using data
from the five sites across three HIC, where the predicted changes in
incidence of VT and NVT IPD was within 95% predictive intervals of
the observed impact for all sites except England and Wales [47].
This method was also validated in South Africa, where it accurately
predicted impacts in older children and adults but not in the age
group of children targeted for vaccination – this may be due to
the model not accounting for the direct effectiveness of PCV in pre-
venting VT-IPD and/or not accounting for reduced population sus-
ceptibility to IPD due to increased anti-retroviral therapy uptake in
the HIV population [48]. A similar method used by Flasche et al.
showed that variations in proportion of VT carriage and IPD pre-
PCV was responsible for the observed heterogeneity in PCV impact
across different nine sites in five HIC [15]. This method was also
applied to assess the cost-effectiveness of PCV globally, finding that
PCV is likely to be a cost-effective measure to reduce childhood
mortality and morbidity across all UN regions and most countries.
Dynamic models have also been used to predict PCV impacts on
disease using carriage data, and can be of particular use to policy-
makers since they are able to make projections into the future and
simulate different intervention scenarios. Using a compartmental
dynamic model fitted to pre-vaccination carriage data in Kenya
and validated using post-vaccination carriage and IPD data, Ojal
et al predicted a sustained reduction in VT carriage and a 56%
reduction of overall IPD incidence in the 10 years post-PCV intro-
duction [46]. A similar model explored the potential impacts of
catch-up campaigns in Vietnam, finding that most of the additional
benefit of catch-up campaigns in children occur within the first
three years after PCV introduction [49].
The question of whether we can confidently model pneumococ-
cal vaccine impact on disease in the absence of IPD surveillanceDownloaded for Anonymous User (n/a) at Royal Children's Hospital - J W
For personal use only. No other uses without permissioremains unclear, given our limited understanding of serotype
replacement disease. Drawing conclusions about reductions in VT
disease following reduction or elimination of VT carriage are rela-
tively straightforward. However, in order to accurately predict
replacement disease, we need to understand the factors contribut-
ing to variation in replacement disease observed in HIC. Recent
results from a whole-genome sequencing study suggests local
antibiotic selective pressure influences trends in pneumococcal
lineages and therefore serotype prevalence observed in IPD post-
PCV. For example, a lineage (GPSC55) with penicillin resistance
increased alongside common use of beta-lactams antibiotics for
treating pneumonia in Israel. Whereas, in The Gambia and South
Africa – where cotrimoxazole is widely used to prevent bacterial
infection in people with HIV, a lineage (GPSC26) with cotrimoxa-
zole resistance predominated [50].
The key piece of information added by carriage studies, used by
the models above to accurately model PCV impact on disease in
most settings, is the composition of replacement carriage serotypes
in the post-PCV era. In order to predict disease, the models rely on
the assumption that the invasiveness of a particular serotype is an
intrinsic property of the capsule and does not change following
PCV introduction, and there is some evidence for this [51–53].
However, a recent review by Lewnard and Hanage notes that ser-
otype distributions in carriage are similar in the US and UK and
contribute little to explain the greater IPD burden from serotypes
8, 9N, 12F, 15A in the UK [7]. This may be due to the inability for
cross-sectional carriage studies among healthy children to detect
highly invasive serotypes. For example, serotypes 1, 12F and 5
are highly invasive serotypes that commonly cause outbreaks of
disease but are rarely carried and may only be transiently detect-
able in carriage during outbreaks [54–57]. In the UK, replacement
serotypes 8 and 12F were not detected in carriage studies despite
being increasingly found in invasive disease [58]. Carriage studies
performed in children with ARI, may better identify such invasive
serotypes.
In order to accurately model replacement disease, models may
also need to include other factors, such as prevalence of comorbidi-
ties [59,60], variations in patterns of vaccine coverage (including
subnational heterogeneity in coverage), and different contact pat-
terns between children and older age groups – all of which are
likely to vary considerably both within LMICs and between LMICs
and HICs [61,62]. While including all these elements within a
model are technically feasible, increasing the complexity of models
often comes at the cost of having to make more assumptions
around parameters for which we have limited data. For example,
all of the models above treat VT and/or NVT carriage as a group.
Modelling specific serotypes would require assumptions about
how different serotypes coexist and compete, and there may be
less certainty around serotype-specific parameters. At this stage,
the minimum components needed to robustly model serotype
replacement disease and identify key replacement disease sero-
types is not clear.
To our knowledge, carriage studies have not been used to pre-
dict the impact of PCV on pneumococcal pneumonia, which has a
much higher disease burden than IPD. This would be useful since
current studies of vaccine impact on pneumonia in LMIC are lim-
ited by challenges in accurately diagnosing pneumonia and assess-
ing aetiology. Greenberg et al. have compared carriage in healthy
children against children with radiological pneumonia, in order
to estimate serotype-specific disease potential for childhood pneu-
monia [63]. There are a growing number of carriage studies among
children with pneumonia or ARI. As we begin to amass data about
the impacts of PCV on carriage, pneumonia and IPD in a range of
settings, there is an opportunity to use mathematical models to
better understand and predict vaccine impacts on different disease
outcomes in LMIC. Grieve Lib from ClinicalKey.com.au by Elsevier on March 24, 2021.
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It is well established that there are disparities in the burden of
pneumococcal carriage and disease within populations [64]. Exam-
ining vaccine impact by risk groups enables policy makers to deter-
mine whether the vaccine is working as intended for those most in
need. In Fiji, where rates of pneumococcal carriage and disease are
higher in the Indigenous population compared with the non-
Indigenous population, carriage studies were able to demonstrate
the role of PCV in reducing differences in VT carriage between
the two groups. VT carriage prevalence decreased from 14.8 to
5.6% among non-Indigenous children and from 26.9 to 8.4% among
Indigenous children 12–23 months of age [23,65]. Similar trends
have been observed in both carriage and disease in Australia and
the US [52,66,67].
3.5.4. Antimicrobial resistance
There is growing appreciation of the potential for vaccines to
address the problem of antimicrobial resistance [68]. PCVs can
reduce antibiotic resistant infections through (1) direct reductions
in VT carriage and disease (often more resistant than NVTs) and (2)
reduction in pneumonia and otitis media, therefore less antibiotic
use [68]. Since resistance is associated with antibiotic pressure on
strains carried in the nasopharynx, initial reductions in AMR due to
reductions in VTs are often counteracted by rising resistance in
NVTs over time [69]. Therefore careful monitoring, through car-




The design of pneumococcal carriage studies depends on the
study objectives, feasibility and setting. There are two main study
designs commonly used for carriage studies: serial cross-sectional
surveys, in which participants from a particular population are
recruited for a once-off survey periodically, and prospective car-
riage surveillance, in which participants fulfilling a certain case
definition are recruited over time in an ongoing manner (Table 2).
While the majority of early impact evaluations using carriage were
conducted as cross-sectional surveys, an increasing number of
evaluations are using a combination of study designs or carriage
surveillance alone to evaluate impact. The former is more suited
to community-based studies and the latter is typically health-
centre based. Cross-sectional studies need to be conducted at sim-
ilar time points of the year, since pneumococcal carriage and den-
sity is known to vary according to season [70,71]. Importantly,
cross-sectional studies may not be able to detect transient changes
in carriage e.g. during outbreaks [72].
3.6.2. Study population and recruitment
The populations targeted by carriage studies can be broadly
classified into three main groups: (a) healthy populations recruited
from the community; (b) healthy populations recruited from
health facilities; and (c) populations with acute respiratory infec-
tion (ARI) recruited from health facilities (Table 3).
Studies of healthy children are ideal for describing circulating
pneumococcal serotype populations. They have the advantage of
being easily translated to disease outcomes, using case-carrier
ratios. Community-based studies can avoid the selection bias that
can be associated with recruiting from health facilities, although
they are commonly more resource-intensive to conduct [73].
The rationale for sampling children with respiratory illness is
that the patterns of carriage may better reflect the serotypes caus-
ing disease [74]. A study of 31 paired lung aspirate and nasopha-
ryngeal aspirates in The Gambia, reported that for all but five
cases, serotypes found in lung aspirates were also found inDownloaded for Anonymous User (n/a) at Royal Children's Hospital - J W Grieve Lib from ClinicalKey.com.au by Elsevier on March 24, 2021.
For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.
Table 3
Key features, advantages and disadvantages of different study populations for determining vaccine impact and monitoring pneumococcal serotypes.







Community-wide surveys South Africa
[32]Brazil
[24]
 Ideal for describing circu-
lating serotypes in the
community
 Can be completed in a
short timeframe
 Can be used infer PCV
impacts on IPD using
case-carrier ratios
 Resource-intensive to conduct
 Less likely to detect invasive serotypes in healthy
children compared to children with acute respira-
tory infection[63]
 Random population sampling may be difficult or not
feasible (e.g. if lacking population register)
 Ready access to appropriate infrastructure (includ-
ing minus 80 freezers), may be difficult in remote
areas and therefore findings may not be generalis-






Recruitment of healthy populations in
day-care facilities, schools, aged care












 Can be used infer PCV
impacts on disease using
case-carrier ratios
 Sampling is biased towards populations with access
to health or educational infrastructure, therefore
findings may not be generalisable to the wider
community;
 Less likely to detect invasive serotypes in healthy






Recruitment based at a health-care









 Can be more reflective of
carriage serotypes causing
pneumonia [63]
 Easier access to appropri-
ate infrastructure (includ-
ing minus 80 freezers)
 Carriage may be affected by prior antibiotic use
 Findings may not be generalizable to describe pneu-
mococcal serotypes circulating in the wider
community
 Unable to translate outcomes to IPD using case-car-
rier ratios
6306 J. Chan et al. / Vaccine 37 (2019) 6299–6309nasopharyngeal aspirates [75]. A study fromMozambique compar-
ing serotype distribution of carriage between healthy children and
children with pneumonia after PCV introduction reported that
while distributions were similar, serotype 1 was only detected in
pneumonia cases and pneumonia was associated with VT carriage
[74]. Therefore sampling in this population may better identify the
highly invasive serotypes. However, interpretation of these studies
in terms of their implications for IPD are less clear since case-
carrier ratios, which are based on carriage in healthy children,
are not directly applicable. The degree to which carriage patterns
reflect disease-causing pneumococcal serotypes may also depend
on the specificity of the case-definition for pneumococcal pneumo-
nia. Analyses would also have to account for antibiotic use in the
population, which decreases pneumococcal yield in nasopharyn-
geal samples by 30% when using culture and 5–7% using molecular
methods [76].
Another important consideration are the age and vaccination
status of study populations. In order to evaluate indirect effects,
studies need to include either unvaccinated children or age groups.
A meta-analysis demonstrated a strong correlation between VT
carriage in children and adults, indicating that it is possible to
make informed predictions about adult carriage based on data
from children, which are more widely available [77]. In particular,
studying toddlers or pre-school age children may be useful proxy
for adults, since these age groups drive indirect protection [78].
However, the relevant age group might differ in LMICs, as trans-
mission patterns differ.3.6.3. Study outcomes
To date, VT and NVT carriage prevalence as a proportion of all
participants, which can be interpreted as a proxy for transmission,
has been the most widely used outcome for carriage studies. Some
studies have also reported VT and NVT carriage as a proportion of
pneumococci identified, which may better account for fluctuations
in pneumococcal carriage and highlight early vaccine effects on cir-
culating pneumococcal populations [23,29].Downloaded for Anonymous User (n/a) at Royal Children's Hospital - J W
For personal use only. No other uses without permissioPneumococcal density has been suggested as an important out-
come to consider in PCV evaluations due to emerging evidence for
the role of carriage density in disease and transmission [20–22].
However, there is uncertainty about how best to use and interpret
this outcome given that carriage density is a dynamic process with
no clear cut-offs for either disease or transmission [20]. The Pneu-
monia Etiology Research for Child Health (PERCH) group deter-
mined an optimum density cut-off for pneumococcal pneumonia,
however the cut-off had only limited sensitivity (64%) [20]. Studies
using carriage density as an outcome will also need to consider
other factors known to affect density including age, antibiotic
exposure, acute respiratory infection and viral co-infection [81,82].
Individuals can be colonised by multiple serotypes of pneumo-
cocci simultaneously, and multiple serotype carriage is common in
LMIC, however the importance of detecting multiple serotype car-
riage in vaccine impact studies remains an open question [83].
Lastly, an emerging area of interest is the impact of PCV on antimi-
crobial resistance (AMR) – studies may consider monitoring resis-
tance patterns and measuring the vaccine effectiveness against
AMR.3.6.4. Comparison groups and potential confounders
To determine direct effects (also known as vaccine effective-
ness), studies can compare carriage outcomes among vaccinated
children with unvaccinated children in the post-PCV period– since
both groups benefit from indirect effects, comparison of the two
groups allows researchers to determine the additional direct ben-
efits experienced by vaccinated children [84]. If indicated, we rec-
ommend a study design, where outcome status is assessed for a
cohort of individuals by nasopharyngeal swab and immunisation
records are used to retrospectively ascertain PCV status. While
case-control studies are commonly conducted to assess vaccine
effectiveness against disease outcomes, this study design is chal-
lenging to apply to carriage outcomes, since carriage is asymp-
tomatic and expedited testing (often not feasible in LMICs) is
required to determine case status. We note that vaccine effective-
ness may be difficult to determine in settings with high coverage Grieve Lib from ClinicalKey.com.au by Elsevier on March 24, 2021.
n. Copyright ©2021. Elsevier Inc. All rights reserved.
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vaccinated and unvaccinated groups (insufficient power), and the
population that remains unvaccinated is likely to be quite different
from the general population and there is therefore a strong poten-
tial for confounding. Surveillance studies are often more suited to
determining vaccine effectiveness, since recruitment over time is
more likely to include unvaccinated individuals as programs are
rolled out, whereas carriage surveys conducted one year following
PCV introduction may comprise mostly vaccinated children, espe-
cially if vaccine coverage is high.
To determine indirect effects, researchers can compare unvacci-
nated people within populations where PCV has been introduced
against a separate populations where PCV has not been introduced.
The comparison population can be separated temporally (e.g. pre-
post comparisons) or geographically (e.g. staged introduction of
PCV [either intentionally or unintentionally since programs often
rollout gradually across a country for administrative reasons])
[84]. Comparisons pre- and post PCV introduction need to account
for other factors influencing in carriage prevalence that may have
changed over time. Important risk factors for carriage include:
age, season, viral infection, crowding, smoke exposure and use of
antibiotics [85,86]. Most studies have only a limited period of base-
line carriage data, making it difficult to determine whether
changes post-PCV introduction may in fact be attributable to secu-
lar trends or random variation. In this context, trends in overall
pneumococcal carriage can provide a useful indicator of likely sec-
ular trends in the absence of PCV introduction.3.6.5. Laboratory methods
The World Health Organization guidelines for pneumococcal
carriage studies for recommend collection of a nasopharyngeal
swab with prompt storage in skim milk-tryptone-glucose-
glycerol medium. Culture on selective blood agar media followed
by optochin susceptibility and bile solubility testing remain the
gold standard for pneumococcal identification, however molecular
methods are becoming widely used, with lytA real-time PCR the
recommended option [16]. An advantage of PCR-based methods
is that they can applied quantitatively.
The capsular reaction/swelling test (Quellung reaction) is con-
sidered the gold standard for pneumococcal serotyping, with latex
agglutination being less expensive and cumbersome [16]. Molecu-
lar methods, including PCR, can also be used to conduct pneumo-
coccal serotyping [87]. The PneuCarriage Project evaluated
pneumococcal serotyping methods for use in carriage studies and
identified DNA microarray with a culture-amplification step as
the top-performing method, with a latex sweep method also per-
forming well [88]. Regardless of methodology, serotyping methods
require trained microbiologists and quality control/quality assur-
ance procedures, and their establishment requires time and
resources. In some settings, collaboration with a regional reference
laboratory may be a more practical option rather than conducting
serotyping in country.4. Conclusion
This review highlights the growing body of pneumococcal car-
riage studies in LMICs. While carriage studies have consistently
demonstrated strong direct and indirect vaccine effects of PCV on
carriage, the magnitude of the impact of PCV has varied widely,
likely due to variations in pneumococcal serotype distribution,
transmission patterns, PCV coverage and timeliness of administra-
tion, vaccine effectiveness by setting, population risk factors and
more [7].
Furthermore there remains critical gap in our ability to monitor
serotype replacement disease in LMIC. Our ability to infer diseaseDownloaded for Anonymous User (n/a) at Royal Children's Hospital - J W G
For personal use only. No other uses without permission. Cpatterns using carriage studies is limited by our lack of under-
standing about replacement disease, demonstrated by our inability
to account for the marked variation in replacement disease across
HIC [7]. A more detailed understanding of the factors and processes
involved in the transition from carriage to disease could guide
modelling studies to translate carriage results to disease outcomes.
Carriage studies in LMICs are often structured and funded as
research studies, and the sustainability of this model is uncertain.
In particular, current laboratory methods require substantial
expertise time and resources. Given the important functions that
carriage studies are providing in monitoring PCV impact in LMIC,
the public health community should consider how to improve fea-
sibility and costs, and how these programs can be better integrated
within routine vaccine preventable disease surveillance.
Robust assessments of vaccine impact are required as policy
makers consider adopting or funding PCV programs, review poten-
tial changes to PCV schedules, and plan for the roll-out of newer
generations of pneumococcal vaccines. Some middle-income coun-
tries are yet to introduce the vaccine and many former low-income
countries are transitioning from receiving Gavi support and need
to consider self-financing existing programs. From a global per-
spective, not every country requires an impact evaluation, however
there needs to be sufficient evidence generated across different
settings in order to inform vaccine policy. In this context, carriages
studies can provide useful information to inform cost-effectiveness
assessments and evaluate newer vaccines and novel vaccination
strategies. However, comparisons across settings, in order to assess
vaccination strategies for example, may be challenging given dif-
ferences in baseline pneumococcal epidemiology and health
systems.5. Search strategy and selection criteria
References for this review were identified through searches of
PubMed for articles published from 2000 to July 2018, by use of
the terms ‘‘pneumococcal vaccine”, ‘‘pneumococcal conjugate vac-
cine”, ‘‘carriage”, and ‘‘colonization” (supplemented post-hoc with
studies from late 2018 and early 2019). We adapted filters pre-
pared by the Cochrane Collaboration to restrict references to those
reporting on LMICs. Relevant studies were also identified by
reviewing abstracts from the 11th International Symposium on
Pneumococci and Pneumococcal Diseases (ISPPD), reports from
the International Vaccine Access Center, Johns Hopkins Bloomberg
School of Public Health and expert consultation. Data extraction
(Table 1) was performed on published and preprint studies only.
Risk of bias was assessed using the Risk of Bias in Non-
randomized Studies of Interventions (ROBINS-I) tool.[89] Detailed
assessments are available in Supplementary Tables 2–4.6. Contributors
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